Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Advanced Chart

Key Stats

Today's Range
$6.48
$6.48
50-Day Range
$6.43
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
Acquisition of Freeline by Syncona Becomes Effective
Acquisition of Freeline by Syncona Becomes Effective
Freeline Therapeutics Shareholders Approve Acquisition by Syncona
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
See More Headlines

FRLN Stock Analysis - Frequently Asked Questions

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its earnings results on Tuesday, November, 9th. The company reported ($12.90) EPS for the quarter, topping the consensus estimate of ($15.20) by $2.30.

Freeline Therapeutics shares reverse split on the morning of Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/09/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FRLN
CIK
1810031
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.5939)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-150.46%
Return on Assets
-97.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.07 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
4,340,000
Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:FRLN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners